N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial

This study seeks to elucidate the benefits of NAC augmentation (2-4 grams/day) compared to placebo in the treatment of OCD, in a 24-week, multi-centre, randomized, double-blind, placebo controlled trial. It is hypothesized that NAC will be superior over placebo for improving OCD symptoms as measured by a reduction in Y-BOCS scores from baseline against each subsequent time point (W4, W8, W12, W16, W20 and W24). Additional benefits are anticipated for relieving anxiety as well as improving mood, functioning and overall quality of life.
The dataset relates to the clinical trial ACTRN12616000847415 N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial. This data cannot be shared publicly due to ethics approval conditions. To discuss this data, please contact the NICM Health Research Institute [e-mail].

本研究旨在阐明一项为期24周的多中心随机双盲安慰剂对照试验中，N-乙酰半胱氨酸（N-acetyl cysteine，简称NAC）增效治疗（每日2~4克）对比安慰剂用于强迫症（Obsessive-Compulsive Disorder，简称OCD）治疗的获益。本研究假设，相较于安慰剂，NAC可更有效地改善强迫症症状，该获益以耶鲁-布朗强迫症量表（Yale-Brown Obsessive Compulsive Scale，简称Y-BOCS）评分较基线在各后续随访时间点（第4周、第8周、第12周、第16周、第20周及第24周）的降幅作为评估指标。预期该干预措施还可额外缓解焦虑症状，并改善情绪状态、社会功能及整体生活质量。
本数据集对应临床试验ACTRN12616000847415《N-乙酰半胱氨酸（NAC）增效治疗强迫症（OCD）：一项24周随机双盲安慰剂对照试验》。由于伦理审批相关要求，本数据集无法公开共享。若需就本数据集进行沟通探讨，请联系NICM健康研究所（邮箱：[e-mail]）。